CN
Imaging Mass Cytometry(IMC)

The use of metal elements as antibody labels enables the simultaneous detection of 40+ markers in the same field of view, enabling systematic analysis of tissue structure cells and infiltrating immune cells.

 

Technical Advantages

Comprehensive

Multi-parameter immunohistochemistry assay with 40+ protein markers in a single sample

In-depth

Images can be obtained with subcellular resolution preserving tissue structure and cellular morphology

Precise

No autofluorescence interference, avoiding complex compensation calculations

Flexible panel design

Marker combinations can be flexibly personalized

Sample Types

A wide range of sample types, from difficult to obtain free cell samples, to precious FFPE samples or frozen tissue sections.

Application Direction
  •  

    Drug development

    Mechanism of efficacy
    Exploration of efficacy markers
    Exploration of resistance mechanisms

  •  

    Study of tumours

    Develop
    Metastatic relapse (medicine)
    Efficacy/prognosis/diagnostic markers
    Spatial heterogeneity mapping

  •  

    Immunity and Infection Sciences

    Inflammatory
    Immune disease
    Infection class

  •  

    Neuroscience

    Tumours of the nervous system
    Nervous system infection
    Neurodegenerative disease

  •  

    Tissue diseases

    Disease diagnosis
    Disease typing
    Treatment of the disease and its prognosis

  •  

    Developmental biology

    Embryonic development
    Organogenesis

Application Cases
  • Circ Res | IMC maps single-cell protein modifications in spatiotemporal mapping of myocardial ischaemia-reperfusion injury in mice
    Professor Wang Li's team at the State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, Chinese Academy of Medical Sciences, used IMC to map the spatio-temporal structure and post-translational modifications of mouse cardiac cellular structure after IRI with single-cell resolution and found that H3K9me3 in the endothelial cells is an important potential target for the treatment of cardiac pathological remodelling after IRI.
  • Nature | IMC Uncovering the single-cell spatial landscape of the lung cancer immune microenvironment
    Single-cell technologies reveal the complexity of the tumour immune microenvironment with precise resolution. Most clinical diagnoses rely on histopathological stratification of tumour subtypes, but little is known about the spatial mapping of single-cell phenotypes in these stratified subgroups. This study characterised the immune microenvironment of 416 non-small cell lung cancer samples by IMC, resolved 1.6 million cells in depth, and analysed the correlation between cellular immune profiles and activation status and patient clinical outcomes.
  • Nature | IMC Uncovering the single-cell spatial immune landscape of primary and metastatic brain tumours
    The study used IMC to describe the tumour microenvironment in 139 patients with high-grade glioma (Glioma) and 46 patients with brain metastases (BrM), revealing differences in the immune landscape between primary tumours and brain metastases of different solid carcinomas through single-cell analyses of more than 1.1 million cells in 389 high-dimensional histopathological images, as well as identifying, in glioblastoma patients, an association with amyeloperoxidase (MPO)-positive macrophage population associated with long-term survival. The findings provide insights into the biology of primary and metastatic brain tumours, reinforcing the value of integrating spatial resolution into single-cell datasets to dissect the microenvironment of cancer.
  • Nature | IMC predicts immune efficacy in triple-negative breast cancer
    By mapping multicellular tumour ecosystems in situ in TNBC with IMC technology, the researchers identified key predictors of the ICB response and showed that ICB uniquely remodels tumour architecture.The application of IMC technology in this article demonstrates that the systematic mapping of complete tumour ecosystems can enable precise immuno-oncology.

Panel

Customised
Services

COPYRIGHT©Infinity Scope Multi-Omics Biotechnology Co. Ltd., All rights reserved. 浙ICP备2023015471号-1